LTP·01learntopeptide
Cognitive & neuroPeptideEvidence B3 cited

N-Acetyl Selank

Acetylated Selank Analog

aka N-Acetyl Selank Amidate · Selank amidate

An acetylated Selank analogue researched for extended anxiolytic and nootropic activity via enhanced enzymatic stability.

Molecular wt
793.9g/mol
Formula
C35H59N11O10
Half-life
1 h
clinical
Tmax
30 min
Route
Intranasal (also subcutaneous)
PubChem
133082488

Sequence

One-letter7 residues

TKPRPGP

Three-letter

Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH

Read this before quoting the sequence
N-terminally acetylated form of Selank. Selank itself is Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), a synthetic analogue of the immunopeptide tuftsin (TKPR) extended with the C-terminal tripeptide Pro-Gly-Pro. The PubChem entry for N-Acetyl Selank (CID 133082488) shows acetylation on the N-terminal threonine and a free C-terminal proline carboxylic acid - i.e. acetylated but NOT amidated, despite the common vendor name 'N-Acetyl Selank Amidate'.
Source ↗

Mechanism of action

N-Acetyl Selank is a synthetic peptide that modulates the expression of genes involved in neurotransmitter synthesis and metabolism, particularly serotonin and dopamine. It enhances the stability of enkephalins, which are natural peptides that regulate mood and anxiety. The N-acetylation increases its resistance to enzymatic degradation, allowing for prolonged activity in the central nervous system.

What the evidence actually shows

Grade B

There are limited human trials specifically on N-Acetyl Selank. Existing studies on Selank suggest potential anxiolytic and cognitive benefits, but direct evidence for the acetylated version is sparse. More robust clinical trials are needed to confirm these effects in humans.

Regulatory status

Status
Not approved as a medicine by the FDA, EMA or MHRA. The N-acetyl derivative specifically has no approval or clinical trial record anywhere.
Clinical stage
No clinical trials of N-Acetyl Selank were identified. All clinical data relate to the parent peptide Selank, studied in Russia.
UK
research_compound

In the UK, N-Acetyl Selank is considered a research compound and is not approved for medical use by the MHRA.

Source ↗

Pharmacokinetics

Half-life
1 h
Tmax
30 min
Absorption
subcutaneous
Elimination
renal
Washout
1 days
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

N-Acetyl Selank amidate specifically has no published human or animal dosing. The unmodified parent peptide Selank is a registered Russian intranasal drug and has been studied in Russian anxiety trials (62 patients vs medazepam; 40 patients as add-on to phenazepam), but those papers' retrievable records do not state a milligram dose, and rodent work uses 300 ug/kg intranasally. Nothing supports a 250-750 mcg human figure for the acetylated form.

ClinicalApproved labelling or a published human trial
PreclinicalAnimal studies — not a human dose

  • Selank 300 ug/kg intranasally (5 uL per nostril), once daily, in an unpredictable chronic mild stress model, alone and with diazepam 1 mg/kg orally

    rat · intranasal · PMID 28280289

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

Commonly circulatedNot established by any study
Dose
250-750 mcg/dose
Frequency
1-2x daily

Why this isn't evidence
N-Acetyl Selank amidate is a chemically modified analogue with no published human or animal dosing at all, and the 250-750 mcg figure traces to vendor dosing pages rather than to any trial of either the analogue or the parent peptide.

This figure is shown because it is what circulates and what people search for — not because it is supported. Cycle lengths in particular tend to be convention copied between compounds rather than anything derived from a compound's own pharmacokinetics.

No established human dose
No approved label or completed human trial establishes a dosing regimen for this compound. Anything presented as a standard protocol for it — anywhere — is someone's convention rather than a finding.

Handling and storage

No compound-specific stability data exists
No peer-reviewed or regulatory stability data specific to N-Acetyl Selank, or to Selank, was located. Only generic lyophilised-peptide handling guidance exists. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Commonly reported
  • ·Mild headache
  • ·Nasal irritation
Rarely reported
  • ·Allergic reactions
Contraindications
  • ·Pregnancy
  • ·Breastfeeding
  • ·"Severe psychiatric disorders"
Drug interactions
  • ·MAO inhibitors - potential for increased serotonin levels

Reported combinations

Reported as synergistic
  • ·L-theanine
  • ·"Rhodiola rosea"
Reported as antagonistic
  • ·Alcohol

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
casNumber, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent, regulatory.wada

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Cognitive & neuro

ARA-290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR) without stimulating erythropoiesis. Provides neuroprotection, anti-inflammatory, and tissue repair effects.
CAQK
Brain-injury-homing tetrapeptide targeting chondroitin sulfate proteoglycans at injury sites.
Cerebrolysin
A porcine-derived neuropeptide complex researched for neuroprotection, cognitive recovery, and stroke rehabilitation.